Seth Klarman
Baupost Group
Seth Klarman JAZZ PHARMACEUTICALS PLC stake
total: 272
Baupost Group JAZZ trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Held since:
- 2023 Q1
- Held for:
- 6 quarters
- Latest activity:
- 2024 Q3
According to 2026 Q2 report, Seth Klarman doesn't hold any JAZZ PHARMACEUTICALS PLC (JAZZ) shares. To date, the estimated cost basis is nearly $126.29 for "buy" trades and estimated average "sell" price is $106.73. Baupost Group first purchased JAZZ in 2023 Q1, initially acquiring 478,696 shares. Since the initial investment in JAZZ PHARMACEUTICALS PLC (JAZZ), Baupost Group has made 4 more transactions.
When did Seth Klarman sell JAZZ PHARMACEUTICALS PLC (JAZZ)?
Seth Klarman sold off the entire JAZZ PHARMACEUTICALS PLC (JAZZ) position in 2024 Q3.
When did Seth Klarman buy JAZZ PHARMACEUTICALS PLC (JAZZ)?
Seth Klarman first invested in JAZZ PHARMACEUTICALS PLC (JAZZ) in 2023 Q1 at the reported quarter-end price of $146.33 per share.
What's the cost basis of Baupost Group's JAZZ stake?
The estimated cost basis for JAZZ PHARMACEUTICALS PLC (JAZZ) stake is around $126.29 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $126.29
- Weighted AVG sell price:
- $106.73
Seth Klarman's historical trades in JAZZ PHARMACEUTICALS PLC
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$106.73
|
|
-100% (-1,274,248)
|
-3.74%
|
|
2024 Q2
|
3.74%
|
1,274,248
|
$106.73
|
$136,000,000
|
+52.84% (+440,552)
|
+1.29%
|
|
2023 Q4
|
2.24%
|
833,696
|
$123.00
|
$102,545,000
|
+23.75% (+160,000)
|
+0.43%
|
|
2023 Q2
|
1.49%
|
673,696
|
$123.97
|
$83,518,000
|
+40.74% (+195,000)
|
+0.43%
|
|
2023 Q1
|
1.20%
|
478,696
|
$146.33
|
$70,048,000
|
new
|
+1.2%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.